The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review

医学 肿瘤科 内科学 弥漫性大B细胞淋巴瘤 危险系数 国际预后指标 比例危险模型 突变 淋巴瘤 置信区间 生物 生物化学 基因
作者
Pengpeng Xu,Rong Shen,Zi‐Yang Shi,Shu Cheng,Li Wang,Yang Liu,Lu Zhang,Ruiqi Huang,Xiaopeng Ma,Xikun Wu,Hui Yao,Yiling Yu,Weili Zhao
出处
期刊:Clinical Lymphoma, Myeloma & Leukemia [Elsevier BV]
卷期号:22 (12): e1051-e1058.e1 被引量:5
标识
DOI:10.1016/j.clml.2022.08.006
摘要

Previous studies have shown that diffuse large B-cell lymphoma (DLBCL) subtype with both B-cell antigen receptor complex-associated protein beta chain (CD79B) and myeloid differentiation primary response 88 mutations (MYD88) had inferior outcome under standard immunochemotherapy. However, the prognostic significance of CD79B alone in DLBCL has not been fully elucidated. We conducted a meta-analysis to investigate the role of CD79B mutation on overall survival (OS) in patients with DLBCL.We performed literature search in PubMed and Embase databases and followed PRISMA guidelines to select publications for analysis. The primary and secondary outcome was OS and progression-free survival (PFS) respectively. Hazard ratio (HR) for OS/PFS in CD79B mutant group with that in wild-type group in R-chemotherapy patients was either estimated using Cox proportional hazard model from the studies with individual participant level data or extracted from the original publication with aggregated results.Nine eligible studies with survival information according to CD79B mutation status were included in this meta-analysis. The pooled hazard ratio for OS was 1.38 (95% CI, 1.13-1.70; p = 0.0021) for CD79B mutation, providing evidence that CD79B mutation was unfavorable prognostic factor for survival in DLBCL patients treated with immunochemotherapy. We identified the inferior prognostic impact of CD79B mutation was independent from well-established prognostic model in DLBCL, International Prognostic Index. The predictive power of CD79B mutation was stronger than that of MYD88 mutation.This meta-analysis revealed that CD79B mutation could be a key biomarker for DLBCL disease progression and future mechanism-based target therapy in DLBCL needs to be studied.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无私的芹发布了新的文献求助10
刚刚
无私的芹发布了新的文献求助10
刚刚
无私的芹发布了新的文献求助30
刚刚
无私的芹发布了新的文献求助10
刚刚
无私的芹发布了新的文献求助10
刚刚
无私的芹发布了新的文献求助10
刚刚
ll应助科研通管家采纳,获得10
1秒前
ll应助科研通管家采纳,获得10
1秒前
小马甲应助科研通管家采纳,获得10
1秒前
1秒前
科研通AI2S应助科研通管家采纳,获得10
1秒前
1秒前
1秒前
Ava应助李李李采纳,获得10
1秒前
张叮当发布了新的文献求助10
3秒前
3秒前
Xuu完成签到,获得积分10
3秒前
小强给博修的求助进行了留言
3秒前
随意发布了新的文献求助10
4秒前
lalala发布了新的文献求助10
4秒前
33发布了新的文献求助10
5秒前
搜集达人应助moon采纳,获得10
5秒前
小静发布了新的文献求助10
5秒前
5秒前
joyemovie完成签到,获得积分10
6秒前
6秒前
F123456完成签到,获得积分10
7秒前
8秒前
9秒前
9秒前
9秒前
虾仁炒饭发布了新的文献求助10
10秒前
12秒前
橘子海完成签到,获得积分10
12秒前
666发布了新的文献求助10
12秒前
万能图书馆应助搞怪熊猫采纳,获得10
13秒前
虚幻尔阳发布了新的文献求助10
14秒前
呵呵发布了新的文献求助10
14秒前
14秒前
枯蚀完成签到,获得积分10
15秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969557
求助须知:如何正确求助?哪些是违规求助? 3514377
关于积分的说明 11173836
捐赠科研通 3249692
什么是DOI,文献DOI怎么找? 1794979
邀请新用户注册赠送积分活动 875537
科研通“疑难数据库(出版商)”最低求助积分说明 804836